24/7 Market News Snapshot 26 September, 2024 – Pasithea Therapeutics Corp. Common Stock (NASDAQ:KTTA)

September 26, 2024

DENVER, Colo., 26 September, 2024 (247marketnews.com) – (NASDAQ:KTTA) are discussed in this article.
Pasithea Therapeutics Corp (NASDAQ:KTTA) is currently witnessing a significant bullish trend, with its stock price surging to $5.113 in pre-market trading, reflecting a remarkable increase of 32.98% from the prior close of $3.845. The trading activity has been robust, with a volume of 596.86K shares exchanged, indicating strong investor confidence and enthusiasm surrounding the biopharmaceutical company’s prospects.

This surge in stock performance coincides with the announcement of promising results from Pasithea’s Phase 1 clinical trial of PAS-004, an innovative macrocyclic MEK inhibitor aimed at treating neurofibromatosis type 1 (NF1) and various advanced solid tumors. The trial, which included six patients, has yielded encouraging outcomes, particularly highlighting one patient with stage 3 colon cancer who has exhibited prolonged stable disease after being treated with multiple therapies. Notably, no treatment-related adverse events or dose-limiting toxicities have been reported, a significant achievement given the common side effects associated with MEK inhibitors.

The pharmacokinetic profile of PAS-004 further underscores its potential, featuring a long half-life of approximately 70 hours, allowing for less frequent oral dosing. This characteristic not only improves patient adherence but also minimizes peak plasma toxicities, marking a significant advancement over earlier MEK inhibitors.

Dr. Tiago Reis Marques, CEO of Pasithea, expressed optimism regarding the initial findings, emphasizing the differentiated safety profile of PAS-004 and its potential efficacy in challenging cases. As the company advances with additional dosing cohorts, it is poised to redefine treatment options for patients suffering from NF1 and other related conditions, keeping stakeholders informed of further developments as the trial progresses.

Related news for (KTTA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.